Enantiospecificity of glutamate carboxypeptidase II inhibition

Takashi Tsukamoto, Pavel Majer, Dilrukshi Vitharana, Chiyou Ni, Bunda Hin, Xi Chun M. Lu, Ajit G. Thomas, Krystyna M. Wozniak, David C. Calvin, Ying Wu, Barbara S. Slusher, David Scarpetti, George W. Bonneville

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Two representative glutamate carboxypeptidase II (GCP II) inhibitors, 2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid 2 and 2-(3-mercaptopropyl)pentanedioic acid 3, were synthesized in high optical purities (>97%ee). The two enantiomers of 2 were prepared from previously reported chiral intermediates, (R)- and (S)-2-(hydroxyphosphinoyl-methyl) pentanedioic acid benzyl esters 8. The synthesis of (R)- and (S)-3 involves the hydrolysis of (R)- and (S)-3-(2-oxo-tetrahydro-thiopyran-3-yl)propionic acids, (R)- and (S)-11, the corresponding optically pure thiolactones delivered by chiral chromatographic separation of the racemic 11. GCP II inhibitory assay revealed that (S)-2 is 40-fold more potent than (R)-2. In contrast, both enantiomers of 3 inhibited GCP II with nearly equal potency. The efficacy observed in subsequent animal studies with these enantiomers correlated well with the inhibitory potency in a GCP II assay.

Original languageEnglish (US)
Pages (from-to)2319-2324
Number of pages6
JournalJournal of medicinal chemistry
Issue number7
StatePublished - Apr 7 2005
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery


Dive into the research topics of 'Enantiospecificity of glutamate carboxypeptidase II inhibition'. Together they form a unique fingerprint.

Cite this